Acute Liver Failure

Signature availability Acute Liver Failure

This indication is not ranked and not for sale. What follows is the measurement we hold and why it is not enough, published because it is the part of this work most likely to be useful to someone attempting the same thing.

The signature is not small — it is measured on a different gene space. It carries 940 genes, but our score is a rank correlation computed only over those it shares with the 978-gene LINCS landmark set, and that intersection is 940. At that depth, 99.2% of draws reproduce the ranking (measured at 200 shared genes).

The 940 landmark genes this signature covers

Direction as recorded in the source signature. This is the entire overlap the score was computed over, published so you can judge whether that subset is biologically coherent for this indication and re-run it yourself.

Compounds this signature surfaced alphabetical · deliberately unranked

Shown so you can see what a 940-gene correlation produces, not so you can act on it. Ordering is withheld because at this depth the order is a tie-break artifact rather than a measurement. Our own structural screen and registered-trial counts are shown rather than hidden.

• azacitidine
• chloroquine
• etoposide
• isotretinoinSTRUCTURAL ALERT
• menadioneSTRUCTURAL ALERT
• perhexiline
• teniposide
• tramadol1 registered trial in this indication

What would change this

A signature for this indication measured on a platform that overlaps the landmark set more deeply. Our floor is 300 genes; 200 is the deepest point at which we have actually measured reliability. We cannot tell you which genes would matter most here — that would need a curated disease-gene map for this indication, which we do not hold and are not going to assert. If you have a deeper signature for this disease and want it scored against our library, that is a conversation we are glad to have.